A Phase II Study of Cabozantinib (XL-184) Monotherapy in Patients With Advanced Cholangiocarcinoma After Progression on First or Second Line Systemic Therapy
Phase of Trial: Phase II
Latest Information Update: 13 Feb 2017
At a glance
- Drugs Cabozantinib (Primary)
- Indications Cholangiocarcinoma
- Focus Biomarker; Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 13 Feb 2017 Results published in the Cancer journal.
- 22 Sep 2015 Planned End Date changed from 1 Jun 2015 to 1 Jun 2016, as reported by ClinicalTrials.gov record.